Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
Published on April 25, 2017 in New-York, New-York (USA)
New York, N.Y. – April 25, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene
edited CAR T-cells, today announced that data on its gene-edited allogeneic off-theshelf CAR T-cell immunotherapies (UCART) will be presented at the ASGCT 20th
Annual Meeting. The meeting will be held from May 10th to 13th, 2017 in Washington, D.C., USA.
Oral presentation:
Development of Gene Edited Allogeneic CAR T-Cell Therapy
Philippe Duchateau, PhD. Chief Scientific Officer, Cellectis
Session: 300 - Clinical Advancement of Gene Editing-Moving New Science to the Clinic -
Organized by the Clinical Trials and Regulatory Affairs Committee
Friday, May 12, 2017 from 8:35 AM to 9:10 AM EST
Lincoln 2, 3, 4
Poster presentations:
176 - Genome-Wide Analysis of TALEN® Activity in Primary Cells
Brian Busser, Sonal Temburni, Aymeric Duclert, Philippe Duchateau and Laurent
Poirot
Session: Gene Targeting and Gene Correction I
Wednesday May 10, 2017 at 5:30 PM EST
Exhibit Hall A & B South
114 - UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia Targeting
CD22 with CAR T-cells
Anne-Sophie Gautron, Cécile Schiffer-Mannioui, Alan Marechal, Severine Thomas,
Agnes Gouble, Laurent Poirot, Julianne Smith
Session: Cancer-Immunotherapy, Cancer Vaccines I
Wednesday May 10, 2017 from 5:30 PM to 7:30pm EST
Exhibit Hall A & B South
372 - Manufacturing of Gene-Modified Mouse CAR T-Cells
Laurent Poirot, Brian Busser, Sonal Temburni, Philippe Duchateau
Session: Gene Targeting and Gene Correction II
Thursday May 11, 2017 from 5:15 PM to 7:15 PM EST
Exhibit Hall A & B South
For further information, please contact:
Media contacts:
Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com
IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com